
Tempest Therapeutics fell 96.4% from $9.39 to $0.34, behind the S&P 500's +11.2%. Its worst day was Nov 19 (−48.6%), and its low came Nov 16 at $0.34.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Tempest Therapeutics shares fell 48.6%, while the S&P 500 rose 0.4%.
−48.6%, the year's worst day · S&P 500 +0.4%
Story events cover the past 12 months · Times ET
EPS of $-0.62 beat the $-0.62 estimate on $0.00 revenue.
−12.1% · S&P 500 −0.3%
Tempest Therapeutics shares rose 29.7%, while the S&P 500 fell 0.1%.
+29.7% · S&P 500 −0.1%
EPS of $-0.50 missed the $-0.28 estimate on $0.00 revenue.
−12.4% · S&P 500 −1.2%
EPS of $-0.34 missed the $-0.30 estimate on $0.00 revenue.
−13.2% · S&P 500 −0.2%
Tempest Therapeutics shares rose 60.2%, while the S&P 500 fell 0.4%.
+60.2%, the year's best day, on 105M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $-0.21 beat the $-0.32 estimate on $0.00 revenue.
−10.5% · S&P 500 −1.9%
Where it ended: a close of $0.34 on Nov 16, 2026.
Nothing in the past 12 months.
All TPST dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TPST and SPY from Benzinga historical bars. Not investment advice.